Podcasts about Melanoma

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

Interview with David C. Whiteman, MBBS, PhD, author of A Risk Prediction Tool for Invasive Melanoma. Hosted by Adewole S. Adamson, MD. Related Content: A Risk Prediction Tool for Invasive Melanoma

Interview with David C. Whiteman, MBBS, PhD, author of A Risk Prediction Tool for Invasive Melanoma. Hosted by Adewole S. Adamson, MD. Related Content: A Risk Prediction Tool for Invasive Melanoma

Dr. Alex Meves, distinguished dermatologist at the Mayo Clinic and a spokesperson for SkylineDx, discusses the challenges in diagnosing and treating melanoma and how a new molecular test called Merlin can help improve risk stratification and treatment decisions for patients with early-stage melanoma. Diagnosis and treatment have traditionally used tumor thickness as a primary risk factor. This molecular test measures the expression of genes in the tumor biopsy and can help determine the extent of surgery needed and whether additional therapies may be beneficial. Alex explains, "My department, when I started to work here at Mayo, wanted me to do some translational research, and I had just come back from a postdoc in Germany, at the Max Planck Institute, and I was tasked to get some research going. And so I focused on melanoma because I thought at the time there wasn't a lot of molecular research going on in melanoma that could be translated to patients. And so we started to develop biomarkers, sort of molecular tests that we could apply to tissue, and then help patients with." "Yes, so the problem that our research is focused on is what to do once you're diagnosed with a melanoma. What you want to do is to match the right therapy to the right patient. That's the goal. There are lots of melanomas that might not be very aggressive, and you don't have to do a lot of treatment. And then there's some melanoma that's very aggressive, and you want to do lots of treatment, but it's not always obvious which melanoma is low risk and which melanoma is high risk. And so this idea of risk stratification at diagnosis becomes very important to match therapy to patients." #skincancer #melanoma #SkylineDx #PersonalizedMedicine #PrecisionDiagnostics skylinedx.com Download the transcript here

Dr. Alex Meves, distinguished dermatologist at the Mayo Clinic and a spokesperson for SkylineDx, discusses the challenges in diagnosing and treating melanoma and how a new molecular test called Merlin can help improve risk stratification and treatment decisions for patients with early-stage melanoma. Diagnosis and treatment have traditionally used tumor thickness as a primary risk factor. This molecular test measures the expression of genes in the tumor biopsy and can help determine the extent of surgery needed and whether additional therapies may be beneficial. Alex explains, "My department, when I started to work here at Mayo, wanted me to do some translational research, and I had just come back from a postdoc in Germany, at the Max Planck Institute, and I was tasked to get some research going. And so I focused on melanoma because I thought at the time there wasn't a lot of molecular research going on in melanoma that could be translated to patients. And so we started to develop biomarkers, sort of molecular tests that we could apply to tissue, and then help patients with." "Yes, so the problem that our research is focused on is what to do once you're diagnosed with a melanoma. What you want to do is to match the right therapy to the right patient. That's the goal. There are lots of melanomas that might not be very aggressive, and you don't have to do a lot of treatment. And then there's some melanoma that's very aggressive, and you want to do lots of treatment, but it's not always obvious which melanoma is low risk and which melanoma is high risk. And so this idea of risk stratification at diagnosis becomes very important to match therapy to patients." #skincancer #melanoma #SkylineDx #PersonalizedMedicine #PrecisionDiagnostics skylinedx.com Listen to the podcast here

After a summer podcasting break, Jim Joyce and I are back and on this episode of #TheShot of #DigitalHealth Therapy, we finally cornered the legendary Erik de Heus, CEO of SkinVision (yes, only 173 episodes in… shame on us). From biking along Amsterdam canals to catching curveballs in Dutch baseball, to scaling energy startups and now leading SkinVision, Erik's story is a mix of persistence, humility, and “just follow your dream” wisdom. If you've ever wondered how a kid bossing his friends on the playground ends up building digital health business that catch melanoma early and save lives at scale - this one's for you. Fun mentions as always: Steve Seuntjens HLTH Inc. Martin Kelly ⧉ 00:00 – 02:00 | Opening banter – Jim & Eugene finally get Erik on the mic. ⧉ 02:00 – 06:00 | Early career & HP days – Amsterdam to California and back. ⧉ 06:00 – 09:00 | Childhood & sports – Football, baseball, and bossing friends. ⧉ 10:00 – 15:00 | Energy startup journey – From inception to €500M revenue. ⧉ 15:00 – 20:00 | Scaling challenges – Processes, people, and persistence. ⧉ 22:00 – 28:00 | Philips DirectLife – Competing with Fitbit + coaching layer. ⧉ 30:00 – 33:00 | Birth of PHS Capital – Early digital health investing. ⧉ 34:00 – 41:00 | SkinVision origins – Melanoma detection at scale. ⧉ 42:00 – 47:00 | Aligning incentives – Insurance, NHS, and consumer trust. ⧉ 47:00 – 54:00 | Erik's advice & future vision – Follow your dream, validate the problem.

The incidence and prevalence of cutaneous melanoma in the US and worldwide have increased over the last 5 decades. JAMA Review Author John Kirkwood, MD, discusses the epidemiology, risk factors, treatment, and prevention of melanoma with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Cutaneous Melanoma ----------------------------------- JAMA Editors' Summary

In today's episode, supported by Immatics, we spoke with Jason Luke, MD, about the development of the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in the ongoing phase 3 SUPRAME trial (NCT06743126) in patients with previously treated, unresectable or metastatic cutaneous melanoma. In our conversation, Dr Luke discussed the rationale for evaluating IMA203 in patients with cutaneous melanoma, the mechanism of action of this novel drug, the design of this study, earlier data that support the continued investigation of this agent in this population, and what these findings may mean for the future of TCR therapy in melanoma.

We're honored to welcome Dr. Carol Shields, one of the world's leading ocular oncologists and Director of the Oncology Service at Wills Eye Hospital, to the Eye Believe Podcast by A Cure In Sight.

Ted Komenda 54 year old Melanoma patient and Dr. Beth Buchbinder.

Jason talks to dermatologist Dr. Mohiba Tareen about some melanoma cases in the news and the increased awareness of this deadly disease.

3pm Hour: Jason talks about the experience of bringing his youngest to college, and how life-changing that feels. Then he talks with dermatologist Dr. Mohiba Tareen about the spotlight being shined on the deadly disease of melanoma.

O cantor Clemente, intérprete de sucessos como “Vais Partir”, faz uma reflexão sobre a sua vida e a sua carreira. Aos 69 anos, o artista acredita que está a passar a melhor fase da sua vida e que agora pode, finalmente, dizer aquilo que pensa. Numa entrevista emotiva, Clemente recorda também o momento, há cinco anos, em que lhe foi diagnosticado um melanoma de grau quatro: “Entrei no carro e chorei durante 15 minutos. Que seja feita a vontade de Deus”. Este programa foi inicialmente emitido na SIC a 29 de junho de 2024, recorde aqui o testemunho do cantor com a versão podcast do 'Alta Definição'. A sinopse deste episódio foi criada com o apoio de IA. Saiba mais sobre a aplicação de Inteligência Artificial nas Redações da Impresa.See omnystudio.com/listener for privacy information.

Melanoma hisses "I sue you beeelyun dollursss" at Hunter Biden. Hunter doesn't blink. Secretary HotMama's squeeze, Corey, can't get his dream job as her C.o.S., so he has to stay a man ho'. Russia conveniently hacks Court System. "Are you listening, Russia?" Wanna bet they have the Maxwell GJ testimony now?

Meet Ashley Morgan — a true rarity in the ocular melanoma community. Before her diagnosis, Ashley was already navigating life completely blind. In this powerful and inspiring conversation, Ashley shares her extraordinary journey, resilience, and the realities of facing a cancer diagnosis without sight.   Her story is one of courage, hope, and the unwavering belief that even in darkness, you can still shine.

Dr. Ravi Johar, Chief Medical Officer for United Healthcare of Missouri and Illinois, joins to show to talk about Melanoma, and other types of Skin Cancer.

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:Kelly Romo, PharmD, BCOPManager, Oncology Medical Drug Management and Customer InitiativesBlue Cross Blue Shield MichiganDetroit, MichiganShawna Kraft, PharmD, BCOPClinical Pharmacist, SpecialistMichigan Medicine, Rogel Cancer CenterClinical Associate ProfessorUniversity of Michigan College of PharmacyAnn Arbor, MichiganResources:Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO

- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO

- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO

- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:Kelly Romo, PharmD, BCOPManager, Oncology Medical Drug Management and Customer InitiativesBlue Cross Blue Shield MichiganDetroit, MichiganShawna Kraft, PharmD, BCOPClinical Pharmacist, SpecialistMichigan Medicine, Rogel Cancer CenterClinical Associate ProfessorUniversity of Michigan College of PharmacyAnn Arbor, MichiganResources:Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO

- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO

This week, Bobbi Conner talks with MUSC Dr. Graciela De Jesus about melanoma skin cancer and prevention strategies.

Bailey O'Brien is an 18-year surthriver of melanoma skin cancer. She was diagnosed three times with melanoma and the third time was considered stage 4 with the cancer in her neck, lung and spine. At that time she pursued alternative treatments and was healed in 10 weeks. She attributes her healing to the Radical Remission healing factors, hard work and the grace of God. www.baileyobrien.com www.instagram.com/baileyobrien330 www.facebook.com/baileyobrien330 Radical Remission Docuseries episode _____________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube ____________ Join the Radical Remission Thriver Community today! The NEW Radical Remission Thriver Community is an innovative, supportive, and educational platform designed to empower individuals on healing journeys, especially those facing cancer or chronic illness. Drawing inspiration from the Radical Remission movement—which explores the holistic factors contributing to unexpected remissions—this online community will serve as a hub for sharing experiences and knowledge, fostering connection, and providing encouragement.  This unique community is designed to inspire, uplift, and connect individuals who are thriving beyond a diagnosis. Whether you are living with a diagnosis yourself, supporting a loved one, or seeking stories of resilience, you'll find a place of understanding and encouragement here. Join the Community - anyone can join the community and attend the monthly events at our special introductory drop-in price of $10 per event for the month of August. In September the drop-in price will be $20 per event. Click here to join the community monthly events!  

The Australian sun is relentless when it comes to UV rays throughout the year, and it is always wise to check your skin thoroughly for any odd-looking spots or changes. 

Aislinn Walsh, lost her 32-year-old husband, Tom, to melanoma in April last year // Amy Nolan, Director of Clinical Affairs with The Irish Cancer Society.

Missy and Hillary are back! On this episode they talk about the latest with Hillary and melanoma. Upcoming Fundraiser!Hats for Hillary: Sunday, August 10th, 2-5pm, Lake WinnebagoIf you'd like to attend, please reach out to missywilt@gmail.com or call/text Missy.If you can't make the event, but want to donate, you can venmo Hillary at: @hillarycastanedaThanks for listening!

Dr Max Gulhane and Zaid Dahhaj explore the intricate relationship between circadian biology, sun exposure, and skin health. They discuss the contradictions in current sun exposure recommendations, the role of melanin as a protective factor, and the importance of aligning circadian rhythms for optimal skin function.The conversation also delves into the impact of diet on photosensitivity and the potential links between lifestyle choices and skin cancer. Overall, the discussion emphasizes a holistic approach to health that incorporates understanding the body's natural rhythms and the benefits of sunlight.SUPPORT THE REGENERATIVE HEALTH PODCAST 

8 Brain Tumors. Stage 4 Cancer. No Chemo. 13 Years Cancer-Free.What happens when the doctors say, “There's nothing more we can do”?For Georges Cordoba, it was the beginning—not the end.In this astonishing episode, Georges shares his raw, miraculous journey through 10 years of cancer treatment, including 4 brain surgeries, 2 inoperable tumors, and the moment he walked away from conventional medicine—and into divine surrender.He chose holistic healing.He chose emotional release.He chose faith.And now, he coaches others through the very fire he walked through.

Today's guest is Janna "Starshine" Jones, a survivor of Stage IIb Melanoma, leading her to become a volunteer for several organizations and a member of the Board of Directors for Epic Experience. Starshine is Janna's Epic Experience Camp name, and it fits her so perfectly. She shines as bright as the stars and radiates joy and love.We talk about the power of community, rediscovering play in our lives, connecting with others in this "cancer club", journalling, perseverance and finding joy in even the hard times, and so much more! Resources:AIM at Melanoma Foundation: https://www.aimatmelanoma.org/Epic Experience: https://www.epicexperience.org/Be Well Therapy: https://www.bewelltherapy.net/Janna's Facebook: https://www.facebook.com/janna.jones.775Follow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L'Huillier, CEO of Scancell, about how the company develops novel immunotherapy products for the treatment of multiple cancers, as well as its recently announced partnership with the NHS Cancer Vaccine Launch Pad, and latest data release from the Phase 2 clinical SCOPE study in melanoma. L'Huillier discusses their melanoma-specific vaccine, and more broadly this pivotal time in immuno-oncology and possibilities on the near horizon. You can also listen to episode 194a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

In this episode, Board Certified Dermatologist, Dr. Jen Haley, discusses: - How does a Basal Cell Cancer present on the skin - Who is predisposed to Basal Cell Cancer & Squamous Cell Cancer? - What are normal changes and abnormal changes with moles? - What are the different things that can grow on your body over time? - Does it reduce your risk of getting melanoma by removing all of your moles? - When to seek expertise from a Board Certified Dermatologist?   Watch this episode on The Radiance Revealed YouTube Channel: https://youtu.be/uJ6L-d-52D0   PRODUCTS / RESOURCES:   Follow Dr. Jen Haley on Instagram @drjenhaley - instagram.com/drjenhaley Connect on LinkedIn:  http://linkedin.com/in/jennifer-haley-md-faad-a4283b46 Book a consultation with Dr. Haley here:  https://app.minnect.com/expert/DrJenHaley Dr. Haley's favorite skincare:  https://www.alumiermd.com?code=5HUKRDKW Dr. Haley's favorite supplements (15% discount): https://us.fullscript.com/welcome/hhaley   #radiancerevealedpodcast

When uveal melanoma spreads to the liver, it's difficult to treat with systemic therapies, but percutaneous hepatic perfusion (PHP) offers an alternative. In this panel discussion, Venkatesh Krishnasamy, M.D., Christy Broman, M.D., and John Dubay, M.D., explain how PHP delivers high-dose chemotherapy directly to the liver while minimizing toxicity. They walk through candidacy, recovery, and how this approach compares to surgery or immunotherapy. Learn how coordination across specialties makes this liver-directed therapy possible.

In this episode I speak with Jenn Frederick who is a cancer survivor who was diagnosed with stage 4 metastatic melanoma and thought that her life was about to come to an end.  You won't believe how she found out she had melanoma, how it didn't look how you might think, and all the incredible challenges she faced during her battle with cancer.Sometimes life throws us huge curveballs and if we are open to it, the silver lining in those dark heavy clouds can lead us to our calling in life like it did for Jenn. She may have began her journey with cancer with a sense of hopelessness and despair, but somehow along the way she was able to transform her fear and doubt into a positive and confident mindset that has led to miraculous results.Take time to listen to this episode and learn just how important mindset is when you are fighting advanced cancer and how Jenn is now inspiring other people to do that too. She knows the power of positivity and believes supporting others on their own journey is her true calling in life.I am sharing her email here because Jenn wants to be there for you too if you are facing any monumental challenges that feel overwhelming and hopeless. jennyk2874@yahoo.comI am also sharing the link to donate to melanoma research. If you are inspired to donate on behalf of Jenn, you can email her to get a direct link for that.https://melanoma.orgClick on the platform of your choice to listen to the latest podcast episode with Jenn, follow the podcast, and write a review so we can spread the news and reach more people! Apple Podcasts https://podcasts.apple.com/us/podcast/the-power-of-community-collaboration-in-sb-podcast/id1548758744Spotify https://open.spotify.com/show/4RWxW7Ni1EHTAywriOwY9z?si=d9c181834529414dGoogle Podcasts https://podcasts.google.com/search/The%20Brain%20BS%20PodcastAmazon Music https://music.amazon.com/podcasts/09208f98-6c21-4fea-abbf-14a495cabd09/the-brain-bs-podcast-learning-to-live-consciouslyI Heart Radiohttps://www.iheart.com/podcast/269-the-brain-bs-podcast-learn-76710324/Pandorahttps://www.pandora.com/podcast/the-brain-bs-podcast-learning-to-live-consciously/PC:60845If you or a loved one are facing a big challenge like advanced cancer, I highly recommend you listen to this episode.Jenn's energy and mindset are contagious and may just change the trajectory of your own battle with cancer.If you want to get in touch with me or connect to get creative about a collaboration, click on the link below.https://www.thebrainbs.com/

Unveiling the Connection: Dr. Keira Barr on Stress, Skin Health, and the Mind-Body ParadigmIn this episode of The Girl Doc Survival Guide, Dr. Keira Barr, a dermatologist specializing in somatic psychodermatology, shares her personal journey of discovering early melanoma and the ensuing health challenges that led her to explore the mind-body connection. Dr. Barr discusses the critical role of stress in skin and overall health, highlighting the importance of recognizing and addressing body signals. She emphasizes the need for a holistic approach to wellness that includes proper diet, mindful movement, and adequate sleep. The conversation delves into adaptive strategies for handling stress, such as breath work and recognizing personal triggers, to maintain equilibrium in the face of the demands of medical training and professional life.00:00 Introduction to Dr. Keira Barr00:26 Personal Journey: From Dermatologist to Somatic Psycho Dermatology01:09 The Wake-Up Call: Diagnosing Her Own Melanoma01:56 Connecting the Dots: Mind-Body Medicine04:12 Lifestyle Changes for Better Health06:13 The Impact of Medical Training on Health07:26 Understanding and Managing Stress11:01 The Nervous System and Stress Response17:10 Practical Tips for Stress Management19:57 Final Thoughts on Skin and Mental Health

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Luis Herrero entrevista a Ángeles Flórez, jefa del servicio de Dermatología en el Hospital Clínico Universitario de Santiago de Compostela.

“Vax to the Future: Cancer Immunity Revolution

In today's episode, supported by Immatics, we had the pleasure of speaking with Justin Moser, MD, about the ongoing phase 3 SUPRAME trial investigating the PRAME-directed T-cell receptor T-cell therapy IMA203 vs treatment of physician's choice in patients with previously treated, unresectable or metastatic cutaneous melanoma. Dr Moser is an associate clinical investigator, a melanoma and cutaneous oncology specialist, and a phase 1 trialist at HonorHealth Research Institute in Scottsdale, Arizona; as well as a research associate professor at the Arizona State University School of Medicine and Advanced Medical Engineering. In our exclusive interview, Dr Moser discussed the unique mechanism of action of IMA203, previously reported phase 1 data with this agent in patients with melanoma, and the design and potential future implications of SUPRAME. 

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

What happens when you're forced to stop doing what you love—and rebuild your life from the inside out? In this deeply moving episode of All Talk Oncology, host Kenny Perkins sits down with Leah Adams, a melanoma survivor, passionate runner, and daughter of a stage four cancer fighter. Diagnosed at just 26 years old with Stage 1A melanoma, Leah shares how cancer interrupted her daily running routine—and how she eventually turned pain into power. From being unable to run post-surgery, to completing multiple marathons, Leah's story is a powerful testament to the strength of the human spirit and the power of reframing your mindset. Whether it's her honesty about guilt, body image, or mental recovery—this conversation is full of hard truths, healing lessons, and undeniable hope. Key points discussed: Leah's diagnosis at age 26 and her emotional reaction to stopping running The surgeries she underwent and how melanoma impacted her body and mindset Why she believed she gave herself cancer—and how she forgave herself How running became both her therapy and her triumph The shift in self-talk and mindset that changed her emotional healing Her public vulnerability through social media and how it helped others Her journey through frequent skin checks, biopsies, and long-term follow-ups Crossing the five-year cancer-free mark and what that milestone meant Why she now advocates for skin checks and sun protection Her mission to use her story to spread awareness and hope   Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM.   SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook JOIN OUR FREE COMMUNITY: Facebook Community WEBSITE: https://www.alltalkoncology.com

Hello Sunday is a skincare brand on a mission to make SPF a daily essential, not just a beach-day afterthought. Founded by Amy Ford after spending years under the intense Australian sun, the brand was born from her realization that sun protection is crucial year-round—even on cloudy days in the UK. Amy returned home with a clear vision: to create affordable, effective SPF products that combine skincare benefits with broad-spectrum protection. She teamed up with a dedicated group of skincare lovers and formulation experts to bring that vision to life. Hello Sunday's formulas are designed to fit seamlessly into any routine, promoting healthy, protected skin every day because every day is a SUN day.In this episode, Amy also discusses:The risk of exposure to UV rays even at low levelsBeing new and different merging skincare and sun careExpensive doesn't mean betterWhy using SPF is the #1 thing you can do for your skin to age healthily Entering in the US in Sephora and growing in this marketWe hope you enjoy this episode and gain valuable insights into Amy's journey and the growth of www.us.hellosundayspf.com. Don't forget to subscribe to the Glam & Grow podcast for more in-depth conversations with the most incredible brands, founders, and more.Be sure to check out Hello Sunday at www.us.hellosundayspf.com and on Instagram at @hellosundayspfRated #1 Best Beauty Business Podcast on FeedPostThis episode is brought to you by WavebreakLeading direct-to-consumer brands hire Wavebreak to turn email marketing into a top revenue driver.Most eCommerce brands don't email right... and it costs them. At Wavebreak, our eCommerce email marketing agency helps qualified brands recapture 7+ figures of lost revenue each year.From abandoned cart emails to Black Friday campaigns, our best-in-class team manage the entire process: strategy, design, copywriting, coding, and testing. All aimed at driving growth, profit, brand recognition, and most importantly, ROI.Curious if Wavebreak is right for you? Reach out at Wavebreak.co